RIGL
Rigel Pharmaceuticals

12,388
Mkt Cap
$509.06M
Volume
913,225.00
52W High
$43.72
52W Low
$14.47
PE Ratio
5.24
RIGL Fundamentals
Price
$28.38
Prev Close
$30.65
Open
$30.09
50D MA
$32.50
Beta
1.21
Avg. Volume
464,459.00
EPS (Annual)
$0.9886
P/B
6.21
Rev/Employee
$1.09M
Loading...
Loading...
News
all
press releases
Rigel Pharmaceuticals (RIGL) Tops Q3 Earnings and Revenue Estimates
Rigel (RIGL) delivered earnings and revenue surprises of +56.99% and +12.80%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·7h ago
News Placeholder
More News
News Placeholder
Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update
Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update PR Newswire SOUTH SAN FRANCISCO...
PR Newswire·8h ago
News Placeholder
Rigel Gears Up to Report Q3 Earnings: Here's What to Expect
RIGL's rising Tavalisse sales, along with incremental sales from Rezlidhia and Gavreto, could power another earnings beat in the quarter to be reported.
Zacks·4d ago
News Placeholder
Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update
Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial...
PR Newswire·7d ago
News Placeholder
Are Investors Undervaluing Rigel Pharmaceuticals (RIGL) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks·21d ago
News Placeholder
After Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Rigel (RIGL)
Rigel (RIGL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks·22d ago
News Placeholder
Can RIGL's Oncology Portfolio Create Long-Term Value Beyond Tavalisse?
Rigel's Tavalisse drives strong sales, but expansion with Rezlidhia, Gavreto, and pipeline candidates could shape its long-term growth story.
Zacks·1mo ago
News Placeholder
Should Value Investors Buy Rigel Pharmaceuticals (RIGL) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks·1mo ago
News Placeholder
Rigel (RIGL) Loses 27.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Rigel (RIGL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks·1mo ago
News Placeholder
RIGL vs. FOLD: Which Biotech Stock Offers Better Growth Potential?
Rigel and Amicus are advancing rare disease therapies, with rising sales from key drugs fueling growth prospects in 2025.
Zacks·1mo ago

Latest RIGL News

View

Advertisement|Remove ads.

Advertisement|Remove ads.